Rationale for a Titratable Fixed-Ratio Co-Formulation of a Basal Insulin Analog and a Glucagon-Like Peptide 1 Receptor Agonist in Patients With Type 2 Diabetes
Current Medical Research and Opinion - United Kingdom
doi 10.1080/03007995.2018.1541790
Full Text
Open PDFAbstract
Available in full text
Categories
Date
November 27, 2018
Authors
Publisher
Informa UK Limited